GeoVax Labs Inc (GOVX)

[3DYOGI]

Investment Highlights:

Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)
Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV and Ebola animal models
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry.

https://www.geovax.com/clinical-pipeline.html

https://www.geovax.com/news.html

http://www.voanews.com/a/partially-effective-hiv-vaccine-could-help-turn-corner-on-pandemic/3776689.html

https://www.geovax.com/images/uploads/analyst_reports/Report_GOVX_2_.pdf

HIV vaccine is worth $5 Billion GOVX will be a $20.00 stock sooner than later.

Under 4 Million market cap less than 49 Million floating world renown scientist heading there vaccines in cancer and pandemics unmet medical needs. Millionaires will be made from these levels.


$GOVX